GLA and Fabry disease: Currently available treatment options for Fabry disease include three enzyme replacement therapy (ERT) agents (agalsidase alfa [not available in the United States], agalsidase beta, and pegunigalsidase alfa) and one oral pharmacological chaperone (migalastat, only for patients with amenable mutations) [13, 14].